Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Yatharth Hospital & Trauma Care Services Ltd. Share Price
Day's Range
Day's Range
Low
₹856.25
High
₹889.90
Price Summary
| Previous Close | ₹876.15 |
|---|---|
| Day's Range | ₹856.25 - ₹889.90 |
| Open | ₹875.00 |
| 52 Week Range | ₹485.00 - ₹887.85 |
| Volume | 6,64,675 |
| Market Cap | ₹0.01 |
| Previous Close | ₹830.60 |
|---|---|
| Day's Range | ₹828.75 - ₹889.80 |
| Open | ₹870.05 |
| 52 Week Range | ₹484.90 - ₹887.15 |
| Volume | 39,911 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 5,823.55 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 49.69 |
| TTM EPS (₹) | 17.37 |
| P/E Ratio | 31.35 |
| Book Value(₹) | 4.80 |
| PAT Margin (%) | 14.83 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 14.35 |
| Trade Value ( ₹ in Lacs) | 331.50 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 49.69 |
| TTM EPS (₹) | 17.37 |
| P/E Ratio | 31.35 |
| Book Value(₹) | 4.80 |
| PAT Margin (%) | 14.83 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 14.35 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1104.11 | 4197.91 |
| Expenses | N/A | N/A |
| PBT | 296.22 | 1131.14 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 222.53 | 839.94 |
About Yatharth Hospital & Trauma Care Services Ltd.
| Founded | 2008 |
|---|---|
| Managing Director | Kapil Kumar |
| NSE Symbol | YATHARTH |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,42,725.29 | 1,838.40 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,82,775.12 | 6,780.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,764.01 | 4,579.25 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,20,200.38 | 8,400.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,007.26 | 1,408.40 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,098.01 | 1,311.15 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,04,542.68 | 1,063.95 | 835.50 - 835.50 |
| Lupin Ltd. | 1,04,222.36 | 2,284.50 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,02,422.13 | 2,458.25 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 99,587.17 | 1,002.00 | 903.00 - 903.00 |
No Records Found
Latest News
Yatharth Hospital & Trauma Care Services informs about voting results and scrutinizer report
In furtherance to its notice dated April 09, 2026 regarding the Postal Ballot by the Company, seeking approval of shareholders by means of special resolution through remote E-voting, to approve the creation of security by way of charge/ mortgage/hypothecation and/or otherwise pursuant to section 180(1)(a) of the companies act, 2013, Yatharth Hospital & Trauma Care Services has informed that the members of the Company have approved the resolution as stated in the Postal Ballot Notice, with requisite majority. The company has enclosed the declaration of the results of Postal Ballot made by the Company, including the voting results in the prescribed format under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Also, it has enclosed the Scrutinizer’s Report dated May 14, 2026, issued by Saurav Upadhyay, Practicing Company Secretary. This disclosure will also be hosted on Company's website:https://www.yatharthhospitals.com/investors/corporate-announcements.
Park Medi World informs about acquisition
Oxygenta Pharma - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 496.14 | 494.67 | 0.30 | 1129.82 | 1092.99 | 3.37 | 1129.82 | 1092.99 | 3.37 |
| Other Income | 1.73 | 0.49 | 253.06 | 2.86 | 13.09 | -78.15 | 2.86 | 13.09 | -78.15 |
| PBIDT | 2.87 | -19.05 | -115.07 | -150.80 | -87.76 | 71.83 | -150.80 | -87.76 | 71.83 |
| Interest | 18.08 | 21.28 | -15.04 | 47.77 | 19.61 | 143.60 | 47.77 | 19.61 | 143.60 |
| PBDT | -15.21 | -40.33 | -62.29 | -198.57 | -107.37 | 84.94 | -198.57 | -107.37 | 84.94 |
| Depreciation | -2.41 | -2.34 | 2.99 | 23.23 | 36.14 | -35.72 | 23.23 | 36.14 | -35.72 |
| PBT | -12.80 | -37.99 | -66.31 | -221.80 | -143.51 | 54.55 | -221.80 | -143.51 | 54.55 |
| TAX | 4.24 | -16.48 | -125.73 | -46.09 | -40.53 | 13.72 | -46.09 | -40.53 | 13.72 |
| Deferred Tax | 4.24 | -18.08 | -123.45 | -46.09 | -42.13 | 9.40 | -46.09 | -42.13 | 9.40 |
| PAT | -17.04 | -21.51 | -20.78 | -175.71 | -102.98 | 70.63 | -175.71 | -102.98 | 70.63 |
| Equity | 369.84 | 369.84 | 0.00 | 369.84 | 369.84 | 0.00 | 369.84 | 369.84 | 0.00 |
| PBIDTM(%) | 0.58 | -3.85 | -115.02 | -13.35 | -8.03 | 66.23 | -13.35 | -8.03 | 66.23 |
Divi's Lab - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 27930.00 | 25360.00 | 10.13 | 103880.00 | 91980.00 | 12.94 | 103880.00 | 91980.00 | 12.94 |
| Other Income | 1540.00 | 870.00 | 77.01 | 5060.00 | 3520.00 | 43.75 | 5060.00 | 3520.00 | 43.75 |
| PBIDT | 10970.00 | 9680.00 | 13.33 | 39940.00 | 33310.00 | 19.90 | 39940.00 | 33310.00 | 19.90 |
| Interest | 60.00 | 0.00 | 0.00 | 230.00 | 10.00 | 2200.00 | 230.00 | 10.00 | 2200.00 |
| PBDT | 10910.00 | 9680.00 | 12.71 | 38970.00 | 33300.00 | 17.03 | 38970.00 | 33300.00 | 17.03 |
| Depreciation | 1200.00 | 1070.00 | 12.15 | 4610.00 | 4010.00 | 14.96 | 4610.00 | 4010.00 | 14.96 |
| PBT | 9710.00 | 8610.00 | 12.78 | 34360.00 | 29290.00 | 17.31 | 34360.00 | 29290.00 | 17.31 |
| TAX | 2150.00 | 1940.00 | 10.82 | 8290.00 | 7200.00 | 15.14 | 8290.00 | 7200.00 | 15.14 |
| Deferred Tax | -350.00 | -310.00 | 12.90 | -400.00 | -730.00 | -45.21 | -400.00 | -730.00 | -45.21 |
| PAT | 7560.00 | 6670.00 | 13.34 | 26070.00 | 22090.00 | 18.02 | 26070.00 | 22090.00 | 18.02 |
| Equity | 530.00 | 530.00 | 0.00 | 530.00 | 530.00 | 0.00 | 530.00 | 530.00 | 0.00 |
| PBIDTM(%) | 39.28 | 38.17 | 2.90 | 38.45 | 36.21 | 6.17 | 38.45 | 36.21 | 6.17 |
Concord Biotech informs about board meeting
Concord Biotech has informed that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026, inter alia, to consider and approve the audited Standalone and Consolidated Financial Results for the fourth quarter and financial year ended March 31, 2026 along with audit report thereon and subject to approval of shareholders at the ensuing Annual General Meeting, to recommend final dividend on equity shares of the Company.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Yatharth Hospital & Trauma Care Services Ltd. is ₹876.15 as of 2026-05-25.
The market capitalisation of Yatharth Hospital & Trauma Care Services Ltd. is ₹8,314.90 as of 2026-05-22.
The 1-year return of Yatharth Hospital & Trauma Care Services Ltd. is 14.00% as of 2026-05-25.
The P/E ratio of Yatharth Hospital & Trauma Care Services Ltd. is 31.35 as of 2026-05-25.
The 52-week high and low of Yatharth Hospital & Trauma Care Services Ltd. are ₹887.85 and ₹485.00, respectively, as of 2026-05-25.
People Also Ask
Yatharth Hospital & Trauma Care Services Ltd. collaborates with pharmaceutical companies and other healthcare entities through clinical practices, procurement of medical equipment, and integration of healthcare technologies. Its hospitals may also serve as clinical settings for treatment protocols and the use of advanced medical devices, while partnering with suppliers to maintain modern healthcare infrastructure.
Yatharth Hospital & Trauma Care Services Ltd. operates multi-specialty hospitals, primarily located in the National Capital Region (NCR). Its facilities provide a range of healthcare services, including trauma care, cardiology, orthopedics, and critical care, supported by intensive care units and related medical infrastructure.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
